GlassScriptPhysician profile
Mohammed S Azeem
NPI 1144583030
$1,438.63
in general payments reported to CMS, 2019-2025
26 companies · $206 in 2025
The $206 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $27.24 · 2021: $85.86 · 2022: $102 · 2023: $61.86 · 2024: $171 · 2025: $206.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $438.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $438.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $470.21 | 2019-2025 | Tecentriq |
| Merck Sharp & Dohme LLC | $176.59 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $92.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $68.05 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $64.04 | 2019-2025 | Eliquis |
| Celgene Corporation | $59.17 | 2019-2025 | Pomalyst, Reblozyl |
| Janssen Biotech, INC. | $45.71 | 2024-2025 | Rybrevant |
| Regeneron Healthcare Solutions, INC. | $42.73 | 2019-2021 | |
| Tesaro, INC. | $37.98 | 2019 | |
| Tempus Ai, INC | $37.69 | 2024 | |
| Verastem, INC. | $34.89 | 2019 | |
| Lilly USA, LLC | $33.57 | 2019-2022 | |
| Genzyme Corporation | $30.65 | 2019-2022 | |
| Intera Oncology, INC | $27.92 | 2025 | Intera |
| Astellas Pharma US INC | $23.91 | 2024 | Vyloy |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $23.56 | 2024 | |
| Cardinal Health 414 LLC | $23.50 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $23.13 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $22.76 | 2019 | |
| Sun Pharmaceutical Industries INC. | $18.36 | 2019 | |
| Immunogen, INC. | $17.30 | 2023 | Elahere |
| Pharmacyclics LLC, An Abbvie Company | $16.99 | 2019 | |
| Tersera Therapeutics LLC | $16.64 | 2021 | |
| Glaxosmithkline, LLC. | $15.47 | 2025 | Zejula, Jemperli |
| Takeda Pharmaceuticals U.S.A., INC. | $15.11 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammed Azeem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.